{"id":1004278,"date":"2026-09-17T11:29:37","date_gmt":"2026-09-17T15:29:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\/"},"modified":"2026-09-17T11:29:37","modified_gmt":"2026-09-17T15:29:37","slug":"calidi-biotherapeutics-announces-1-2-million-registered-direct-offering","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\/","title":{"rendered":"Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO, Sept.  17, 2026  (GLOBE NEWSWIRE) &#8212; Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (\u201cCalidi\u201d or the \u201cCompany\u201d), a biotechnology company pioneering the development of targeted genetic medicines, today announced that it has entered into a definitive stock purchase agreement with certain accredited investors and\/or qualified institutional buyers for the purchase and sale of 1,025,640 shares of the Company\u2019s common stock, in a registered direct offering, at a per share purchase price of $1.17.<br \/>\u00a0\u00a0<br \/>The closing of the registered direct offering is expected to occur on or about September 18, 2026, subject to the satisfaction of customary closing conditions.<\/p>\n<p align=\"justify\">The gross proceeds to Calidi from the registered direct offering, before deducting offering expenses payable by the Company, are expected to be\u00a0approximately $1.2 million. Calidi intends to use the net proceeds from the offering for working capital and for general corporate purposes.<\/p>\n<p align=\"justify\">The securities described above are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-282456), which was declared effective by the United States Securities and Exchange Commission (\u201cSEC\u201d) on October 10, 2024. The registered direct offering is being made only by means of a prospectus, including a prospectus supplement, which is part of the effective registration statement, that will be filed with the SEC.\u00a0Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC\u2019s website at http:\/\/www.sec.gov.<br \/>\u00a0\u00a0<br \/>This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described therein, nor shall there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.<\/p>\n<p align=\"justify\">\n        <strong>About Calidi Biotherapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Calidi Biotherapeutics (NYSE American: CLDI) is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The Company\u2019s proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations.<\/p>\n<p align=\"justify\">CLD-401, the lead candidate from the RedTail platform, currently in IND-enabling studies, targets metastatic non-small cell lung cancer, head and neck cancer, and other tumor types with high unmet medical need. Calidi continues to advance its pipeline utilizing the RedTail platform including its novel approach to incorporate in situ T-cell engagers in solid tumors.<\/p>\n<p align=\"justify\">Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SGcFsUeJiHtyLG9qpQuuYIgCuoJrETuoZbqf4oxep_bSfAgK-7lnOc4IUsp21YLcdlXrm-aBZyp4fmv-wkVFOV7qHjUt9RIc3jVIKmwspm7MHsTXgBx9NokhTkd9R77RAkiMYZVr8s8F9UK1xpk-BmRU1oFGSHHJcvjJdzywsPaSybv46xEabVm62VkrWjHqz3StC4W36r2H64nkfpRgKbCArt5Dpt4631wmOAfO88mqZgLGpaS26Xbu-N3cFUBaPFbwTeOIEj9Q21gApuXWvkrriQEyj42mbGV3XYuO7pfFbi9hcQdU4LAHoNPz40l833BB3dh28GbgNRH6IP8uSpmKC_bbJwo7xsWj1DSSi7Uu7-QTl5wSNCztYSHa77HEO9Q_M51iQxxO5sEu1F2yBHMUkktALv26wMMrdm2qj-H17L6T4x8zbcwqlhAyzA3p0mJJwN3yVqMN24Lkk_Q_KlVCJEkQDy8AsKldxr_D-avHVOcquZk8_tCWCL28-rMIG4dE5iVqYc5IecS0_1Grg6rkq24KsqRCPbuSYCt4y2ZMqN_HqH-3muOmtzxP7QeWmgrLtstakUxwDdeLL6XuWfc2y-mnLaHD9f4cuf7X0qaAF4yJuECtc8A61m8qvmEEfDGnOt9HM0AcV7rpo58rFkI7rAj-OGkoi1Ijudq47lBXnwoTA1aIs6ZjbzA2To2vqOJbKttgLgsmN8daQGBM7-izjK0ht727Z_4ER_7f1bbKmsRzBeOFMh82hdBiB3Db8kQHjxLJCHXfyoWkX4W8XA==\" rel=\"nofollow\" target=\"_blank\">www.calidibio.com<\/a>\u00a0or view Calidi\u2019s Corporate Presentation\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cHwEczdzBSm1xgViicOo0ztAaGVSm2V3KnD4ioH_wgZg5UFMC9GSIUKkxiko7_ac0cGEPk9IEX-NM_TatGx2Dl1gYVRg5trXK5yRQQE88-ayFB2cjVZCoVgsYksSbQJvMoKNHwzeWrTd1y877ZN24DbTshWgtuICSAyv9qU-TVumNh2KQHSX-oilsEgz9kbOkHbEqJfYti7RP05MRGVPeDoPTtRyTkFXeDSWBgBbEqjIfeecEy59yAlyqptjUfIIssVO3mj698g6bkg1TDwJi5Rt9ebzFimEW5KrDHSUX45J2HvQ3BqyjADmmTqtt7_tA85RWmgaECMFO-UA8cbH1EuxtYDhNHH1Whmua6_hPBaIBnBCSsW-oUegL3TsLx8IlbLphQfIqdLkbfdlZZtkLiW7RuaJrNZllJTRY2uheT1T5vNSQaMSzmAQzba0vE39Hy-ogWgKTKbyCLUxHg16tb-PXA3Xke7gzfK98LCpsBNHZDIwjMQ10s--iK9m87Ocst64dD6xlzKsj12xhyXmA2vqjakBYeKlTPT2IpHaMfNU3s3IeYsSRs1WQwkIusjJSIgv0c2kOcRzjBVUPUzbpfE3Y5WtJgb13iJ1b1ov2QwPGxDskqkp-sthRErXbvk_PhqtiC8Xh908G7erU7kF47DPQf763Wd0bKgO0Zini90YgM8c-4WHCK9XDeSTL_0_G5yNzvJVKLbn-YjNOfNpwMEM3xN_SiFQ0l1rF1pnsdkZxb8ZEnwwdya_hCvNIdoEoRPxb1Ppq7njpvwmt13XjhMKOPVwYcKJQHIhAxRNuvrj5S-APhJb0ulzT1ABSSRF0jx3v_UjPF7vOMybgk91VGp0_7-QpascUKj6nWepSymG-1AZXzVsr4hKVRzg7fRKOwg-ZjCjaBv1IO5snaLgfw==\" rel=\"nofollow\" target=\"_blank\">here<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release may contain forward-looking statements for purposes of the \u201csafe harbor\u201d provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as \u201canticipates,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredicts,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctowards,\u201d \u201cwould\u201d as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, the Company\u2019s plans strategies, priorities and key operational initiatives for fiscal year 2026 and 2027, statements concerning key milestones, including certain pre-clinical data, planned clinical trials, and statements relating to the safety and efficacy of Calidi\u2019s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi\u2019s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates; and, risks related to changes in applicable laws or regulations; manufacturing and supply chain matters; the availability of capital and other resources; and changes in business, market, economic or competitive conditions. Other risks and uncertainties are set forth in the section entitled \u201cRisk Factors\u201d and \u201cCautionary Note Regarding Forward-Looking Statements\u201d in the Company\u2019s annual report filed with the SEC on Form 10-K on March 27, 2026, as may be amended or supplemented by other reports we file with the SEC from time to time. We disclaim any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.<\/p>\n<p>\n        <strong><br \/>\n          <u>Investors Contact:<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Lje5QC6THurdMtJ60ftKZP09V3h9PsC6CIvzXEUIoAW9WCAtTfmJAKZSxjOFtAEP75FHAtCiHeubo_BCDRrsYGHV5EXpvUC5bQqfat2lyT9sGWxub7V-Y5ZNLGe2FPmV9ZiDu0h99PknqKcGjr59PPYC8DmjRwlZtgD8mDgHqBaxyctIQKcV02HZbBjBh-MQlwwBHC6OKyb8kxmh5ouB0wEwm5tXBIJFtPjgv_PiXGBvBUJoqd56d43nTg2QOvH_YqjVYowCEA7kqm37ZROCLg==\" rel=\"nofollow\" target=\"_blank\">IR@calidibio.com<\/a>\u00a0<\/p>\n<p>\n        <strong><br \/>\n          <u>Media Contact:<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oKUMo0QLdtLMtd2rq1bfMmNrHTIglqVltwPlGNq278MLNsG4FDYmCJeUbJ-3M4fQ4e2rJhY-LEAQj_BjtkP6jOa4-e9lmDghDJFzyWqoLcmsJFEIMboPnw4b4iJRww33Ml_AbFf5XWD-DuDJZMZV7QEmQGKVd-oYvj-1vmkjYgmozilzksth5frzXwM2OeAcERS8lto2KATEEvlJIO2N-BGj1LmWzoeqLqMhNWLawJd7E0bzzWZBy28BX6bjgWxZ5WhrN_DzQlKSrJryjER0BA==\" rel=\"nofollow\" target=\"_blank\">PR@calidibio.com<\/a>\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyODcyMSM3ODM4NzY5IzIxOTM4NTQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjNmNDgwYzQtM2E4ZC00ZjYzLWE0MWUtNThmM2U1ZmRmZTkyLTEyMDU0MDctMjAyNi0wOS0xNy1lbg==\/tiny\/Calidi-Biotherapeutics-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) &#8212; Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (\u201cCalidi\u201d or the \u201cCompany\u201d), a biotechnology company pioneering the development of targeted genetic medicines, today announced that it has entered into a definitive stock purchase agreement with certain accredited investors and\/or qualified institutional buyers for the purchase and sale of 1,025,640 shares of the Company\u2019s common stock, in a registered direct offering, at a per share purchase price of $1.17.\u00a0\u00a0The closing of the registered direct offering is expected to occur on or about September 18, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Calidi from the registered direct offering, before deducting offering expenses payable by the Company, are expected to be\u00a0approximately &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1004278","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) &#8212; Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (\u201cCalidi\u201d or the \u201cCompany\u201d), a biotechnology company pioneering the development of targeted genetic medicines, today announced that it has entered into a definitive stock purchase agreement with certain accredited investors and\/or qualified institutional buyers for the purchase and sale of 1,025,640 shares of the Company\u2019s common stock, in a registered direct offering, at a per share purchase price of $1.17.\u00a0\u00a0The closing of the registered direct offering is expected to occur on or about September 18, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Calidi from the registered direct offering, before deducting offering expenses payable by the Company, are expected to be\u00a0approximately &hellip; Continue reading &quot;Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-17T15:29:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyODcyMSM3ODM4NzY5IzIxOTM4NTQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering\",\"datePublished\":\"2026-09-17T15:29:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\\\/\"},\"wordCount\":831,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyODcyMSM3ODM4NzY5IzIxOTM4NTQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\\\/\",\"name\":\"Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyODcyMSM3ODM4NzY5IzIxOTM4NTQ=\",\"datePublished\":\"2026-09-17T15:29:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyODcyMSM3ODM4NzY5IzIxOTM4NTQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyODcyMSM3ODM4NzY5IzIxOTM4NTQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\/","og_locale":"en_US","og_type":"article","og_title":"Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering - Market Newsdesk","og_description":"SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) &#8212; Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (\u201cCalidi\u201d or the \u201cCompany\u201d), a biotechnology company pioneering the development of targeted genetic medicines, today announced that it has entered into a definitive stock purchase agreement with certain accredited investors and\/or qualified institutional buyers for the purchase and sale of 1,025,640 shares of the Company\u2019s common stock, in a registered direct offering, at a per share purchase price of $1.17.\u00a0\u00a0The closing of the registered direct offering is expected to occur on or about September 18, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Calidi from the registered direct offering, before deducting offering expenses payable by the Company, are expected to be\u00a0approximately &hellip; Continue reading \"Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-17T15:29:37+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyODcyMSM3ODM4NzY5IzIxOTM4NTQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering","datePublished":"2026-09-17T15:29:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\/"},"wordCount":831,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyODcyMSM3ODM4NzY5IzIxOTM4NTQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\/","name":"Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyODcyMSM3ODM4NzY5IzIxOTM4NTQ=","datePublished":"2026-09-17T15:29:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyODcyMSM3ODM4NzY5IzIxOTM4NTQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyODcyMSM3ODM4NzY5IzIxOTM4NTQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-announces-1-2-million-registered-direct-offering\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1004278","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1004278"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1004278\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1004278"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1004278"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1004278"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}